Key result
SGLT2 inhibitors have demonstrated significant benefits, including a 35% relative risk reduction with empagliflozin, in reducing hospitalization for heart failure in patients with type 2 diabetes.
Why the study?
Do SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death in patients with type 2 diabetes mellitus?
Do SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors provide consistent benefits in reducing heart failure hospitalizations and cardiovascular death in patients with type 2 diabetes mellitus, regardless of established ASCVD.
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure New Insights From DECLARE-TIMI 58Articles, see p 2516 and p 2528 D iabetes mellitus intersects with cardiovascular disease at every level.Although there has been much focus on understanding atherosclerotic complications, less well appreciated is the relationship between diabetes mellitus and heart failure.In addition to being a key and independent risk factor for the development of heart failure, 1 diabetes mellitus is also one of the most important adverse prognostic factors in those with established heart failure with either reduced or preserved ejection fraction (EF).1,2 Diabetes mellitus is associated with a high prevalence of unrecognized left ventricular diastolic and systolic dysfunction, and it accelerates the development of overt heart failure compared with similar patients without diabetes mellitus.3 In addition to cardiac predictors such as left ventricular dysfunction, hypertrophy, and coronary artery disease, features of diabetes mellitus associated with the development of heart failure include poor glycemic control, longer duration of diabetes mellitus, insulin treatment, and the presence of microvascular complications, such as retinopathy or nephropathy.2,4 Finally, data from randomized trials and registries remind us that heart failure is numerically nearly as common as ischemic complications in patients with type 2 diabetes mellitus and remains one of the leading causes of hospitalizations in this population.1,2 Although conventional risk factor control can reduce ischemic complications, heart failure risk remains a recalcitrant problem in diabetes mellitus for which intensive glycemic control has had little benefit.The serendipitous story of sodium-glucose transporter 2 (SGLT2) inhibitors and heart failure stems from the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), 5 which unexpectedly demonstrated a profound 35% relative risk reduction in hospitalization for heart failure in patients with type 2 diabetes mellitus and established atherosclerotic vascular disease (ASCVD) who were treated with empagliflozin.Two additional SGLT2 inhibitors, canagliflozin and dapagliflozin, have been studied in large cardiovascular outcome trials (the CANVAS [Canagliflozin Cardiovascular Assessment Study] Program 6 and DECLARE-TIMI 58 [Dapagliflozin Effect on Cardiovascular Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes], 7 respectively).Both confirmed the benefit of SGLT2 inhibitors on hospitalization for heart failure (HHF), the composite of HHF or cardiovascular death (HHF/CV death), and renal composite outcomes.Importantly, these latter studies included people with type 2 diabetes mellitus with and without established ASCVD.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2019) conducted an editorial in Type 2 diabetes mellitus and heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors have demonstrated significant benefits, including a 35% relative risk reduction with empagliflozin, in reducing hospitalization for heart failure in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: